公开(公告)号：US10080742B2

公开(公告)日：2018-09-25

申请号：US15497307

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Yong He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D417/14 ,  C07D413/12 ,  C07D413/14 ,  A61K31/42 ,  A61K31/426 ,  A61K31/4725 ,  A61K31/545 ,  A61K31/64 ,  C07D261/08 ,  C07D275/04 ,  C07D277/62

CPC classification number: A61K31/42 ,  A61K31/426 ,  A61K31/4725 ,  A61K31/545 ,  A61K31/64 ,  C07D261/08 ,  C07D275/04 ,  C07D277/62 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20180237471A1

公开(公告)日：2018-08-23

申请号：US15896400

申请日：2018-02-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Jiang Long ,  Peng Dai ,  Brett Granger ,  Jing He

IPC: C07J41/00 ,  C07J43/00

CPC classification number: C07J41/005 ,  C07J9/005 ,  C07J41/0055 ,  C07J43/003 ,  C07J51/00

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US20170334894A1

公开(公告)日：2017-11-23

申请号：US15597423

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Yong He ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D413/12

CPC classification number: C07D413/12 ,  A61K31/42

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20170333399A1

公开(公告)日：2017-11-23

申请号：US15597431

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Xuechao Xing ,  Ruichao Shen ,  Bin Wang ,  Brett Granger ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D225/04 ,  C07D213/127 ,  C07D261/08 ,  C07C317/38

CPC classification number: A61K31/42 ,  C07C317/38 ,  C07D213/127 ,  C07D225/04 ,  C07D261/08

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.

公开(公告)号：US20170304272A1

公开(公告)日：2017-10-26

申请号：US15497359

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Brett Granger ,  Jun Ma ,  Jing He ,  Yong He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  A61K31/422 ,  C07D261/08 ,  C07D413/12

CPC classification number: A61K31/42 ,  A61K31/422 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20230174515A1

公开(公告)日：2023-06-08

申请号：US18073728

申请日：2022-12-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10961272B2

公开(公告)日：2021-03-30

申请号：US16854334

申请日：2020-04-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yong He ,  Brett Granger ,  Xuechao Xing ,  Yat Sun Or

IPC: C07J41/00 ,  C07J43/00 ,  C07J51/00 ,  C07J9/00

Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),

公开(公告)号：US20200331890A1

公开(公告)日：2020-10-22

申请号：US16866778

申请日：2020-05-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10597382B2

公开(公告)日：2020-03-24

申请号：US16113611

申请日：2018-08-27

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Jing He ,  Bin Wang ,  Ruichao Shen ,  Brett Granger ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  A61P13/12 ,  A61P3/10 ,  A61P1/16

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20200062727A1

公开(公告)日：2020-02-27

申请号：US16546736

申请日：2019-08-21

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jing He ,  Brett Granger ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D401/04 ,  C07D401/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).